← Search

Data · dataset · 2026

Dissolving microarray patch-mediated transdermal delivery of anti-Parkinson's agents

Listed in ZivaHub and Deakin Research Online and DMU Figshare — shown once because both records carry DOI 10.17034/32638908.v1

The prevalence of Parkinson’s disease (PD) is regarded as one of the most significant challenges for global health, affecting approximately ten million people worldwide.

Description

Rotigotine (RTG) is a representative dopamine agonist, the first new chemical entity that is only formulated as a transdermal patch (Neupro®, 10 – 40 cm2) for PD treatment. However, the once-daily transdermal administration could be challenging for PD patients as it may likely become a life-long medication.

Furthermore, studies have revealed that long-term repeated transdermal administration can induce application-site skin irritations, leaving the development of alternative formulations with prolonged release and reduced dosing frequency as a pressing issue. Therefore, RTG was formulated into a nanosuspension (NS) formulation and further loaded into dissolving microarray patches (MAPs) that can deposit the drug payload in the skin dermal layer and potentially release the drug in an extended behaviour.

Read the rest (3 more)

The simultaneous delivery of levodopa (LD) and its decarboxylase inhibitor, carbidopa (CD), remains the gold standard therapy for PD. However, the fluctuated pharmacokinetic profile of orally-administered LD can lead to motor complications such as ‘wearing-off’ periods. The currently marketed LD/CD intestinal gel (Duodopa®) offers an option to bypass the oral administration route and facilitate a continuous LD delivery, which gives a more stable plasma concentration than the oral formulation Sinemet®.

However, Duodopa® therapy involves an invasive surgical procedure to implant a jejunal percutaneous endoscopic gastrostomy tube into the small intestine through which LD and CD are infused. Thus, a dissolving MAP formulation was developed for the simultaneous delivery of LD and CD. Formulated MAPs consist of 256 needles (16 x 16, 0.5 cm2) and were investigated in terms of various properties as well as ex vivo studies and in vivo pharmacokinetic profiles.

This original approach offers a solution to deliver these anti-Parkinson’s agent transdermally as alternatives to the conventional formulations.<br><br><i>Thesis embargoed until 31st December 2029 </i>

Links

Where it is published

Catalogue records · 1

Topics

Provenance · 3 source records, 13 field assertions
SourceKeyLast seenRaw
ZivaHuboai:figshare.com:article/3263890813 d agoJSON v1
Deakin Research Onlineoai:figshare.com:article/3263890813 d agoJSON v1
DMU Figshareoai:figshare.com:article/3263890813 d agoJSON v1
FieldAssertionExtractorEvidence
access_levelsource · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0
concepts[disease].local:disease:diseaseenrichment · zivahub uct ac zakeyword-concept-rules@1.0.0title+description (75%)
concepts[field].anzsrc:group:3214enrichment · zivahub uct ac zataxonomy-embedding@1.1.0title+keywords+description (69%)
concepts[field].local:field:earth-environmentalmapping · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0
concepts[field].local:field:earth-environmentalmapping · figshare dmu ac ukconnector:figshare_dmu_ac_uk@1.0.0
concepts[field].local:field:earth-environmentalmapping · dro deakin edu auconnector:dro_deakin_edu_au@1.0.0
concepts[field].local:field:medicine-healthmapping · dro deakin edu auconnector:dro_deakin_edu_au@1.0.0
concepts[field].local:field:medicine-healthmapping · figshare dmu ac ukconnector:figshare_dmu_ac_uk@1.0.0
concepts[field].local:field:medicine-healthmapping · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0
descriptionsource · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0/metadata/dc/description
license_textsource · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0
publication_datesource · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0
titlesource · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0/metadata/dc/title